Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ArriVent BioPharma, Inc. Common Stock (AVBP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: AVBP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $39.43
Year Target Price $39.43
| 6 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 1.08% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 783.81M USD | Price to earnings Ratio - | 1Y Target Price 41.12 |
Price to earnings Ratio - | 1Y Target Price 41.12 | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 15.47 - 36.37 | Updated Date 06/29/2025 |
52 Weeks Range 15.47 - 36.37 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.76 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.1% | Return on Equity (TTM) -49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 607528646 | Price to Sales(TTM) - |
Enterprise Value 607528646 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 34212600 | Shares Floating 15821941 |
Shares Outstanding 34212600 | Shares Floating 15821941 | ||
Percent Insiders 9.74 | Percent Institutions 85.2 |
Analyst Ratings
Rating 4.86 | Target Price 39.43 | Buy 1 | Strong Buy 6 |
Buy 1 | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ArriVent BioPharma, Inc. Common Stock
Company Overview
History and Background
ArriVent BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to treat cancers. Founded in 2021, they aim to address unmet medical needs in oncology through strategic collaborations and in-licensing of promising drug candidates. They went public in January 2024.
Core Business Areas
- Drug Development: Focuses on the clinical development and commercialization of novel oncology therapeutics, primarily in-licensed from other companies.
Leadership and Structure
The leadership team consists of Bing Yao, Ph.D. (CEO), and other experienced executives in the biopharmaceutical industry. The company operates with a focus on strategic partnerships to accelerate drug development.
Top Products and Market Share
Key Offerings
- Furmonertinib: Furmonertinib is a third-generation EGFR inhibitor being developed for non-small cell lung cancer (NSCLC). There is no market share data available at this time. Competitors include Tagrisso (osimertinib) by AstraZeneca, and other EGFR inhibitors.
Market Dynamics
Industry Overview
The oncology therapeutics market is a large and rapidly growing market driven by the increasing prevalence of cancer globally and advancements in cancer treatment. Innovation in targeted therapies and immunotherapies is significantly impacting the market.
Positioning
ArriVent BioPharma is positioning itself as a key player in the oncology space through the development and commercialization of Furmonertinib.
Total Addressable Market (TAM)
The global NSCLC therapeutics market is estimated to be in the tens of billions of dollars. ArriVent's positioning within this TAM depends on the success of Furmonertinib.
Upturn SWOT Analysis
Strengths
- Promising drug candidate (Furmonertinib)
- Experienced management team
- Strategic partnerships and in-licensing approach
Weaknesses
- Reliance on a single key asset
- Limited commercial infrastructure
- Early stage company with limited track record
Opportunities
- Expansion into new oncology indications
- Strategic collaborations with larger pharmaceutical companies
- Potential for accelerated regulatory approval
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- AZN
- MRTX
- TAK
Competitive Landscape
ArriVent BioPharma faces competition from established pharmaceutical companies with larger resources and broader pipelines. Its competitive advantage lies in the potential efficacy and safety profile of Furmonertinib.
Growth Trajectory and Initiatives
Historical Growth: N/A (limited historical data)
Future Projections: Future growth is dependent on the successful development and commercialization of Furmonertinib and other pipeline assets. Analyst estimates should be monitored closely.
Recent Initiatives: Focus on clinical trials for Furmonertinib, expanding pipeline through licensing agreements and commercializing approved therapies.
Summary
ArriVent BioPharma is a new biopharmaceutical company with a promising drug candidate, Furmonertinib. The company is externally innovative, leveraging collaborations and in-licensing to develop its pipeline. Success depends on the clinical success of Furmonertinib and expanding their product offerings. They face competition from larger pharmaceutical companies and regulatory hurdles as a newly formed company. Future prospects look positive, but require sustained execution and success in clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ArriVent BioPharma, Inc. Common Stock
Exchange NASDAQ | Headquaters Newtown Square, PA, United States | ||
IPO Launch date 2024-01-26 | Co-Founder, Chairman, President & CEO Dr. Zhengbin Yao Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://arrivent.com |
Full time employees 52 | Website https://arrivent.com | ||
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.